Dry Eye Disease: Causes, Symptoms, and Evidence-Based Management

Dry eye disease (DED) is a multifactorial disorder of the tear film and ocular surface causing discomfort, visual disturbance, and tear film instability. Prevalence: 5–30% (increases with age, female sex). It is a chronic, often progressive condition requiring long-term management.

Pathophysiology (TFOS DEWS II Classification)

  • Aqueous-Deficient DED: Lacrimal gland dysfunction (Sjögren's, age, medications, graft-vs-host disease).
  • Evaporative DED: Meibomian gland dysfunction (MGD) — 86% of DED. Lipid layer deficiency → rapid tear evaporation.
  • Mixed: Most patients have both components.
  • Neuropathic: Corneal nerve dysfunction (post-LASIK, herpetic, diabetes).

Risk Factors

  • Aging, menopause (androgen decline → MGD).
  • Screen use (↓ blink rate, incomplete blinks).
  • Contact lens wear.
  • Medications: Antihistamines, antidepressants, diuretics, isotretinoin, beta-blockers.
  • Autoimmune: Sjögren's, RA, SLE, scleroderma.
  • Environment: Low humidity, wind, AC/heat, pollution.
  • Rosacea (ocular).

Symptoms

  • Foreign body sensation, grittiness, burning, stinging.
  • Paradoxical tearing (reflex).
  • Blurred vision (improves with blink).
  • Light sensitivity, eye fatigue, contact lens intolerance.
  • Worse late day, reading, screen use, dry environments.

Diagnostic Evaluation

  • Symptom questionnaires: OSDI, SPEED, DEQ-5.
  • TBUT (tear breakup time) <10 sec.
  • Schirmer I <5 mm/5 min (aqueous deficiency).
  • Ocular surface staining (fluorescein cornea, lissamine green conjunctiva).
  • Meibography (MGD structure).
  • Tear osmolarity >308 mOsm/L or inter-eye difference >8.
  • MMP-9 (InflammaDry) — inflammatory marker.

Stepwise Management

Level 1: Education + Environmental + Lubrication

  • Preservative-free artificial tears (carboxymethylcellulose, hyaluronic acid, HP-guar) — 4–6×/day.
  • Gel/ointment at bedtime.
  • Humidifier (30–50%), avoid direct airflow, 20-20-20 rule (screens).
  • Omega-3 (1–2 g EPA+DHA).
  • Lid hygiene (warm compresses 10 min + lid scrubs).

Level 2: Anti-Inflammatory + Therapeutic

  • Topical cyclosporine 0.05% (Restasis) or 0.09% (Cequa) — BID; 3–6 mo for full effect.
  • Lifitegrast 5% (Xiidra) — BID; faster onset.
  • Short-course topical steroid (loteprednol, fluorometholone) — pulse then taper.
  • Punctal plugs (collagen → silicone) — if aqueous deficient, no active inflammation.
  • Oral doxycycline/azithromycin (anti-inflammatory, MGD) — low dose, 1–3 mo.

Level 3: Advanced

  • Autologous serum tears (20–50%).
  • Thermal pulsation (LipiFlow), IPL (intense pulsed light) for MGD.
  • Amniotic membrane graft (Prokera).
  • Scleral lenses (protect surface, vault cornea).
  • Severe: Systemic immunosuppression (Sjögren's), tarsorrhaphy, salivary gland transplant.

Newer Therapies

  • Varenicline nasal spray (Tyrvaya) — cholinergic agonist → tear production.
  • Perfluorohexyloctane (Miebo) — evaporative DED/MGD (lipid layer replacement).
  • Reproxalap (RASP modulator) — investigational.

DED is chronic; management is iterative. Partner with an eye care provider for personalized step therapy.

Eye & Vision Disorders - Related Articles